Lisheng Wang

Lisheng Wang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JLJingfen Li
Jingfen Li
DLDong Li
Dong Li
YXYiming Xu
Yiming Xu
ZGZhenbo Guo
Zhenbo Guo
XLXu Liu
Xu Liu
LWLisheng Wang
Lisheng Wang

1 June 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LWLisheng Wang
Lisheng Wang
YYYejun You
Yejun You
SWSongqing Wang
Songqing Wang
XLXu Liu
Xu Liu
BLBuming Liu
Buming Liu
HYHua Yang
Hua Yang

23 November 2016 in Molecules
Verified
Journal Article
Open access
PDF file
JLJingfen Li
Jingfen Li
YYYong Yin
Yong Yin
LWLisheng Wang
Lisheng Wang
PLPengyun Liang
Pengyun Liang
MLMenghua Li
Menghua Li
HYHua Yang
Hua Yang
In this study, a new series of 16 methyl salicylate derivatives bearing a piperazine moiety were synthesized and characterized. The in vivo anti-inflammatory activities of target compounds were investigated against xylol-induced ear edema and carrageenan-induced paw edema in mice. The results showed that all synthesized compounds exhibited potent anti-inflammatory activities. Especially, the anti-inflammatory activities of compounds M15 and M16 were higher than that of aspirin and even equal to that of indomethacin at the same dose. In addition, the in vitro cytotoxicity activities and anti-inflammatory activities of four target compounds were performed in RAW264.7 macrophages, and compound M16 was found to significantly inhibit the release of lipopolysaccharide (LPS)-induced interleukin (IL)-6 and tumor necrosis factor (TNF)-α in a dose-dependent manner. In addition, compound M16 was found to attenuate LPS induced cyclooxygenase (COX)-2 up-regulation. The current preliminary study may provide information for the development of new and safe anti-inflammatory agents.

27 October 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LWLichuan Wu
Lichuan Wu
GWGuizhen Wang
Guizhen Wang
SLShuaibing Liu
Shuaibing Liu
JWJinrui Wei
Jinrui Wei
SZSen Zhang
Sen Zhang
LWLisheng Wang
Lisheng Wang
Matrine, an active component of root extracts from Sophora flavescens Ait, is the main chemical ingredient of Fufang Kushen injection which was approved by Chinese FDA (CFDA) in 1995 as an anticancer drug to treat non-small cell lung cancer and liver cancer in combination with other anticancer drugs. Owning to its druggable potential, matrine is considered as an ideal lead compound for modification. We delineate herein the synthesis and anticancer effects of 17 matrine derivatives bearing benzo-α-pyrone structures. The results of cell viability assays indicated that most of the target compounds showed improved anticancer effects. Further studies showed that compound 5i could potently inhibit lung cancer cell proliferation in vitro and in vivo with no obvious side effects. Moreover, compound 5i could induce G1 cell cycle arrest and autophagy in lung cancer cells through up-regulating P27, down-regulating CDK4 and cyclinD1 and attenuating PI3K/Akt/mTOR pathway. Suppression of autophagy attenuated 5i induced proliferation inhibition. Collectively, our results infer that matrine derivative 5i bears therapeutic potentials for lung cancer.

12 May 2011 in Journal of Chemical & Engineering Data
Verified
Journal Article
Closed access
YZYang Zhang
Yang Zhang
LWLisheng Wang
Lisheng Wang
RZRonghong Zhou
Ronghong Zhou
XLXiongmin Liu
Xiongmin Liu

1 September 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LWLichuan Wu
Lichuan Wu
SLShuaibing Liu
Shuaibing Liu
JWJinrui Wei
Jinrui Wei
DLDong Li
Dong Li
XLXu Liu
Xu Liu
LWLisheng Wang
Lisheng Wang